Clinical Trials
55 trialsTherapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
Université Catholique de Louvain
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Disc Medicine, Inc
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
National Cancer Institute (NCI)
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Icahn School of Medicine at Mount Sinai
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
MoTD
University of Birmingham
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
PACRIMYEL
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
SICP RCT
University of Rochester
MK-3543-017
Merck Sharp & Dohme LLC
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
University of Southern California
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
AVAJAK
University Hospital, Brest
ACCELERATE
Center for International Blood and Marrow Transplant Research
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
University of California, Irvine
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
City of Hope Medical Center
CALRSUIVI
University Hospital, Angers
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Fred Hutchinson Cancer Center
GR-MPN
Azienda Ospedaliero-Universitaria di Parma
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MPN Research Foundation
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
M.D. Anderson Cancer Center
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
TREATMORE
Icahn School of Medicine at Mount Sinai
PHEMOP
University Hospital, Angers
Two Step Haplo With Radiation Conditioning
Thomas Jefferson University
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
POTAMI-61
Ryvu Therapeutics SA
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
PharmaEssentia
EpiC
University Hospital, Bordeaux
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
University of Virginia
TREG108
Cellenkos, Inc.
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Icahn School of Medicine at Mount Sinai
Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
University of Rochester
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix, Inc.